Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 12:23 am
Share
Kwang Dong Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 1,175.82 million compared to KRW 817.48 million a year ago. Net income was KRW 6,441 million compared to KRW 8,940.88 million a year ago. Basic earnings per share from continuing operations was KRW 157 compared to KRW 218 a year ago. Diluted earnings per share from continuing operations was KRW 157 compared to KRW 217 a year ago. Basic earnings per share was KRW 157 compared to KRW 218 a year ago.
For the nine months, sales was KRW 2,439.72 million compared to KRW 1,810.97 million a year ago. Net income was KRW 17,028.03 million compared to KRW 17,431.9 million a year ago. Basic earnings per share from continuing operations was KRW 415 compared to KRW 424 a year ago. Diluted earnings per share from continuing operations was KRW 415 compared to KRW 424 a year ago. Basic earnings per share was KRW 415 compared to KRW 424 a year ago.
Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.
KWANG DONG PHARMACEUTICAL CO., LTD. 
